Baseline demographics and disease characteristics (ITT population)
| Variable . | Nonintensive pathway (n = 849) . | Intensive pathway (n = 1111) . | ||||||
|---|---|---|---|---|---|---|---|---|
| MP (n = 423) . | CTDa (n = 426) . | CVAD (n = 556) . | CTD (n = 555) . | |||||
| ZOL . | CLO . | ZOL . | CLO . | ZOL . | CLO . | ZOL . | CLO . | |
| (n = 212) . | (n = 211) . | (n = 214) . | (n = 212) . | (n = 278) . | (n = 278) . | (n = 277) . | (n = 278) . | |
| Median age, y (range) | 73 (59-89) | 74 (57-88) | 74 (61-87) | 73 (58-85) | 59 (31-74) | 58 (39-72) | 58 (33-71) | 59 (33-78) |
| Sex, n (%) | ||||||||
| Female | 95 (44.8) | 97 (46.0) | 96 (44.9) | 88 (41.5) | 100 (36.0) | 108 (38.8) | 101 (36.5) | 110 (39.6) |
| Male | 117 (55.2) | 114 (54.0) | 118 (55.1) | 124 (58.5) | 178 (64.0) | 170 (61.2) | 176 (63.5) | 168 (60.4) |
| ISS stage, n (%) | ||||||||
| I | 37 (17.5) | 27 (12.8) | 26 (12.1) | 20 (9.4) | 59 (21.2) | 65 (23.4) | 70 (25.3) | 81 (29.1) |
| II | 63 (29.7) | 93 (44.1) | 76 (35.5) | 80 (37.7) | 93 (33.5) | 98 (25.3) | 105 (37.9) | 84 (30.2) |
| III | 92 (43.4) | 73 (34.6) | 81 (37.9) | 87 (41.0) | 98 (35.3) | 85 (30.6) | 76 (27.4) | 84 (30.2) |
| Data unavailable | 20 (9.4) | 18 (8.5) | 31 (14.5) | 25 (11.8) | 28 (10.1) | 30 (10.8) | 26 (9.4) | 29 (10.4) |
| Hyperdiploidy, n (%)* | ||||||||
| Yes | 56 (26.4) | 71 (33.6) | 61 (28.5) | 61 (28.8) | 70 (25.2) | 93 (33.5) | 89 (32.1) | 78 (28.1) |
| No | 41 (19.3) | 31 (14.7) | 46 (21.5) | 45 (21.2) | 62 (22.3) | 68 (24.5) | 71 (25.6) | 64 (23.0) |
| Data unavailable | 115 (54.2) | 109 (51.7) | 107 (50.0) | 106 (50.0) | 146 (52.5) | 117 (42.1) | 117 (42.2) | 136 (48.9) |
| t(4;14), n (%)* | ||||||||
| Yes | 12 (5.7) | 9 (4.3) | 6 (2.8) | 17 (8.0) | 18 (6.5) | 17 (6.1) | 20 (7.2) | 21 (7.6) |
| No | 90 (42.5) | 100 (47.4) | 102 (47.7) | 98 (46.2) | 118 (42.4) | 152 (54.7) | 144 (52.0) | 129 (46.4) |
| Data unavailable | 110 (51.9) | 102 (48.3) | 106 (49.5) | 97 (45.8) | 142 (51.1) | 109 (39.2) | 113 (40.8) | 128 (46.0) |
| t(11;14), n (%)* | ||||||||
| Yes | 16 (7.5) | 8 (3.8) | 14 (6.5) | 16 (7.5) | 18 (6.5) | 28 (10.1) | 27 (9.7) | 19 (6.8) |
| No | 86 (40.6) | 101 (47.9) | 95 (44.4) | 98 (46.2) | 118 (42.4) | 140 (50.4) | 137 (49.5) | 130 (46.8) |
| Data unavailable | 110 (51.9) | 102 (48.3) | 105 (49.1) | 98 (46.2) | 142 (51.1) | 110 (39.6) | 113 (40.8) | 129 (46.4) |
| Bone disease or other SRE, n (%)† | ||||||||
| Yes (SRE+) | 138 (65.1) | 146 (69.2) | 137 (64.0) | 130 (61.3) | 199 (71.6) | 210 (75.5) | 194 (70.0) | 196 (70.5) |
| No (SRE−) | 72 (34.0) | 60 (28.4) | 71 (33.2) | 75 (35.4) | 77 (27.7) | 65 (23.4) | 82 (29.6) | 76 (27.3) |
| Data unavailable | 2 (0.9) | 5 (2.4) | 6 (2.8) | 7 (3.3) | 2 (0.7) | 3 (1.1) | 1 (0.4) | 6 (2.2) |
| Variable . | Nonintensive pathway (n = 849) . | Intensive pathway (n = 1111) . | ||||||
|---|---|---|---|---|---|---|---|---|
| MP (n = 423) . | CTDa (n = 426) . | CVAD (n = 556) . | CTD (n = 555) . | |||||
| ZOL . | CLO . | ZOL . | CLO . | ZOL . | CLO . | ZOL . | CLO . | |
| (n = 212) . | (n = 211) . | (n = 214) . | (n = 212) . | (n = 278) . | (n = 278) . | (n = 277) . | (n = 278) . | |
| Median age, y (range) | 73 (59-89) | 74 (57-88) | 74 (61-87) | 73 (58-85) | 59 (31-74) | 58 (39-72) | 58 (33-71) | 59 (33-78) |
| Sex, n (%) | ||||||||
| Female | 95 (44.8) | 97 (46.0) | 96 (44.9) | 88 (41.5) | 100 (36.0) | 108 (38.8) | 101 (36.5) | 110 (39.6) |
| Male | 117 (55.2) | 114 (54.0) | 118 (55.1) | 124 (58.5) | 178 (64.0) | 170 (61.2) | 176 (63.5) | 168 (60.4) |
| ISS stage, n (%) | ||||||||
| I | 37 (17.5) | 27 (12.8) | 26 (12.1) | 20 (9.4) | 59 (21.2) | 65 (23.4) | 70 (25.3) | 81 (29.1) |
| II | 63 (29.7) | 93 (44.1) | 76 (35.5) | 80 (37.7) | 93 (33.5) | 98 (25.3) | 105 (37.9) | 84 (30.2) |
| III | 92 (43.4) | 73 (34.6) | 81 (37.9) | 87 (41.0) | 98 (35.3) | 85 (30.6) | 76 (27.4) | 84 (30.2) |
| Data unavailable | 20 (9.4) | 18 (8.5) | 31 (14.5) | 25 (11.8) | 28 (10.1) | 30 (10.8) | 26 (9.4) | 29 (10.4) |
| Hyperdiploidy, n (%)* | ||||||||
| Yes | 56 (26.4) | 71 (33.6) | 61 (28.5) | 61 (28.8) | 70 (25.2) | 93 (33.5) | 89 (32.1) | 78 (28.1) |
| No | 41 (19.3) | 31 (14.7) | 46 (21.5) | 45 (21.2) | 62 (22.3) | 68 (24.5) | 71 (25.6) | 64 (23.0) |
| Data unavailable | 115 (54.2) | 109 (51.7) | 107 (50.0) | 106 (50.0) | 146 (52.5) | 117 (42.1) | 117 (42.2) | 136 (48.9) |
| t(4;14), n (%)* | ||||||||
| Yes | 12 (5.7) | 9 (4.3) | 6 (2.8) | 17 (8.0) | 18 (6.5) | 17 (6.1) | 20 (7.2) | 21 (7.6) |
| No | 90 (42.5) | 100 (47.4) | 102 (47.7) | 98 (46.2) | 118 (42.4) | 152 (54.7) | 144 (52.0) | 129 (46.4) |
| Data unavailable | 110 (51.9) | 102 (48.3) | 106 (49.5) | 97 (45.8) | 142 (51.1) | 109 (39.2) | 113 (40.8) | 128 (46.0) |
| t(11;14), n (%)* | ||||||||
| Yes | 16 (7.5) | 8 (3.8) | 14 (6.5) | 16 (7.5) | 18 (6.5) | 28 (10.1) | 27 (9.7) | 19 (6.8) |
| No | 86 (40.6) | 101 (47.9) | 95 (44.4) | 98 (46.2) | 118 (42.4) | 140 (50.4) | 137 (49.5) | 130 (46.8) |
| Data unavailable | 110 (51.9) | 102 (48.3) | 105 (49.1) | 98 (46.2) | 142 (51.1) | 110 (39.6) | 113 (40.8) | 129 (46.4) |
| Bone disease or other SRE, n (%)† | ||||||||
| Yes (SRE+) | 138 (65.1) | 146 (69.2) | 137 (64.0) | 130 (61.3) | 199 (71.6) | 210 (75.5) | 194 (70.0) | 196 (70.5) |
| No (SRE−) | 72 (34.0) | 60 (28.4) | 71 (33.2) | 75 (35.4) | 77 (27.7) | 65 (23.4) | 82 (29.6) | 76 (27.3) |
| Data unavailable | 2 (0.9) | 5 (2.4) | 6 (2.8) | 7 (3.3) | 2 (0.7) | 3 (1.1) | 1 (0.4) | 6 (2.2) |